Calls on GSK attractive ahead of Advair generic decision – #SaxoStrats

GlaxoSmithKline is the most attractive European healthcare stock in our quant model on equities. But in the short term there is risk of FDA approval of a generic replacement for GSK’s Advair drug around May 10. Because of this tail risk we are playing GSK by buying call options.